Global Life Science Leader [ ]
BGI’s unparalleled understanding of its clients’ competitive landscape in conjunction with best-in-class executive through board level recruiting makes it the search firm of choice with clients that are truly focused on driving their success and bringing exceptional shareholder value.
 CEO Board Executive Learn More Global Life Science Leader [ ] BGI’s unparalleled understanding of its clients’ competitive
landscape in conjunction with best-in-class executive
through board level recruiting makes it the search firm
of choice with clients that are truly focused on driving
their success and bringing exceptional shareholder value. Biotechnology Pharmaceutical Medical Device Contract Services Learn More Global Life Science Leader [ ] BGI’s unparalleled understanding of its clients’ competitive
landscape in conjunction with best-in-class executive
through board level recruiting makes it the search firm
of choice with clients that are truly focused on driving
their success and bringing exceptional shareholder value. Saving Lives Improving Treatments Learn More Maximizing Shareholder Value Finding Cures Helping Clients

Encompassing all Executive through Board Positions in Life Sciences

Director of the Board

Yes

Chief Executive Officer

Yes

Chief Business Officer

Leading publicly traded biopharmaceutical stem cell company.

No

Chairman of the Board

Yes

Chief Financial Officer

Formerly Aastrom Biosciences

Yes

Chief Operating Officer

Yes

Chief Scientific Officer

Leading publicly traded monoclonal antibody & oncology company

No

Executive Vice President, Orthopedics and Chief Operating Officer

Formerly BioMimetic Therapeutics, Inc.

Yes
See More

In The News

With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an expansion and putting more color on its filing plans with the FDA.

https://www.fiercepharma.com/pharma/united-plots-tyvaso-fda-filing-after-repeat-success-lung-disease-portends-new-ipf-standard

The company is looking to work out an arrangement with the U.K. government that would see higher drug prices in exchange for Lilly to continue its U.K. investments, according to a report in The Financial Times.

https://www.fiercepharma.com/pharma/lilly-presses-uk-deal-would-see-higher-nhs-prices-exchange-resumed-investments-ft

Promotional materials for a handful of biologics have found their way into the FDA’s hot seat.

https://www.fiercepharma.com/marketing/bms-novartis-gilead-iovance-biologics-dinged-rare-spate-cber-untitled-letters

After notching a phase 2 trial win, Idorsia’s insomnia med Quviviq is one step closer to potentially becoming a first-in-class treatment for children.

https://www.fiercepharma.com/pharma/idorsia-looks-crack-open-pediatric-insomnia-market-ph2-win-sleep-med-quvivq

The labor union of Samsung Biologics has secured the votes needed to strike, signaling a potential escalation in an impasse over what the union has branded “[u]nresolved governance failures and rigid labor policies” at the company.

https://www.fiercepharma.com/pharma/samsung-biologics-union-gathers-votes-strike-tension-over-wage-governance-talks-mounts

Takeda has started a workforce reduction in the U.S., plotting to cut 634 jobs, as the company aims to save more than $1.26 billion in annual costs.

https://www.fiercepharma.com/pharma/takeda-begins-us-layoffs-part-massive-13b-restructuring

Piper Sandler Spring Biopharma Symposium
Boston, MA April 15-16

Needham & Co. Annual Healthcare Conference
New York, NY April 13-16

Society of Gynecologic Oncology Annual Meeting (SGO)
San Juan, Puerto Rico April 11-13

American Academy of Dermatology (AAD)
Denver, CO March 27-30

Society of Toxicology Annual Meeting (SOT)
San Diego, CA March 22-26

American Society of Clinical Oncology Genitourinary Cancers Symposium
San Francisco, CA February 26-28

See More Events

Read More Articles